YARROW BIOSCIENCE, INC. Revenue from Contract with Customer, Including Assessed Tax
YARROW BIOSCIENCE, INC. (YARW) reported Revenue from Contract with Customer, Including Assessed Tax of $10.64 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-03.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2020-03-03
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $10.14M, a 2159.02% increase year-over-year.
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $497.00K, a 10.69% increase year-over-year.
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for fiscal 2018 was $10.64M, a 132.21% increase from fiscal 2017.
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for fiscal 2017 was $4.58M, a 579.82% increase from fiscal 2016.
- YARROW BIOSCIENCE, INC. revenue from contract with customer, including assessed tax for fiscal 2016 was $674.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $0.00 derived: sum of 2 quarters · filed 2020-03-03 | $10.14M derived: sum of 3 quarters · filed 2020-03-03 | $10.64M 10-K · filed 2020-03-03 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $10.14M derived: sum of 2 quarters · filed 2020-03-03 | $10.64M 10-Q · filed 2019-10-31 | $13.41M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $10.14M 10-K · filed 2020-03-03 | $10.64M 10-Q · filed 2019-08-01 | $13.41M derived: sum of 3 quarters · filed 2020-03-03 | $14.32M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $497.00K 10-K · filed 2020-03-03 | $3.27M derived: sum of 2 quarters · filed 2020-03-03 | $4.18M derived: sum of 3 quarters · filed 2020-03-03 | $4.63M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $2.77M 10-K · filed 2019-02-28 | $3.68M derived: sum of 2 quarters · filed 2019-02-28 | $4.13M derived: sum of 3 quarters · filed 2019-02-28 | $4.58M 10-K · filed 2020-03-03 |
| 2017-09-30 | $909.00K 10-K · filed 2019-02-28 | $1.36M derived: sum of 2 quarters · filed 2019-02-28 | $1.81M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $449.00K 10-K · filed 2019-02-28 | $898.00K 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $449.00K 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $674.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |